The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Japan Drug Makers See Rising Overseas Sales Ratio amid Uphill Battle at Home: Tally
Combined sales of 27 Japanese drug makers rose 3.3% year on year in FY2017, with companies deriving increasing proportions of their revenues from overseas markets, illustrating a tough business environment at home, a Jiho tally shows. The tally covered 27…
To read the full story
Related Article
- Japan Drug Firms’ Average Overseas Sales Ratio Nearly 50%, Offshore Biz Remains Way to Go as Home Market Falters: Tally
May 30, 2019
- Japan Drug Makers Driven by Overseas Sales, See Tepid Revenue at Home: Jiho Tally
December 12, 2017
- FY2016 Sales Dip for 27 Japan Makers, Second-Tier/Mid-Sized Firms Fare Well: Jiho Tally
May 24, 2017
BUSINESS
- Teikoku to Market Medipost’s Knee OA Cell Therapy in Japan
December 22, 2025
- Clinigen Japan Adds 4 Products, Including Takeda’s Buccolam
December 22, 2025
- Meiji Backs US Incubator MBC BioLabs to Boost Open Innovation
December 22, 2025
- Boehringer Passes on Option for Nxera’s Schizophrenia Program
December 22, 2025
- Otsuka Kicks Off Global PIII of Phenylketonuria Drug
December 22, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…